SSTR2 and neoplasm: The presence of SSTR2 on NETs has led to the use of synthetic somatostatin analogs (eg, octreotide and lanreotide) (9–13) and radiolabeled somatostatin analogs (eg, 111In-pentetreotide [Octreoscan] and 177Lu-DOTATATE) (14, 15) for tumor localization and treatment.